YS Biopharma (YS) Set to Announce Quarterly Earnings on Friday

YS Biopharma (NASDAQ:YS) is scheduled to be posting its earnings results before the market opens on Friday, April 19th.

YS Biopharma (NASDAQ:YS) last posted its quarterly earnings results on Monday, January 22nd. The company reported ($0.16) EPS for the quarter. The firm had revenue of $13.64 million during the quarter. On average, analysts expect YS Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

YS Biopharma Stock Performance

Shares of YS traded up $0.08 during mid-day trading on Wednesday, reaching $0.94. 413,726 shares of the stock traded hands, compared to its average volume of 199,102. The company has a quick ratio of 1.09, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a fifty day moving average price of $0.61 and a 200 day moving average price of $0.57. YS Biopharma has a 1 year low of $0.35 and a 1 year high of $2.37.

Hedge Funds Weigh In On YS Biopharma

A number of institutional investors have recently added to or reduced their stakes in YS. XTX Topco Ltd purchased a new stake in shares of YS Biopharma during the 2nd quarter valued at about $31,000. Barclays PLC bought a new position in shares of YS Biopharma in the second quarter worth about $150,000. Finally, FMR LLC purchased a new position in YS Biopharma during the first quarter valued at approximately $1,864,000. Institutional investors own 52.64% of the company’s stock.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.